.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Department of Justice
Novartis
Chinese Patent Office
Baxter
McKinsey
Johnson and Johnson
US Army
Farmers Insurance
Dow
Citi

Generated: November 21, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 201922

« Back to Dashboard
NDA 201922 describes XIMINO, which is a drug marketed by Sun Pharm Inds Ltd and is included in one NDA. It is available from one supplier. There are seven patents protecting this drug. Additional details are available on the XIMINO profile page.

The generic ingredient in XIMINO is minocycline hydrochloride. There are thirteen drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.

Summary for 201922

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:7
Therapeutic Class:Antibacterials
Dental and Oral Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 201922

Ingredient-typeTetracyclines

Medical Subject Heading (MeSH) Categories for 201922

Suppliers and Packaging for NDA: 201922

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
XIMINO
minocycline hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL 201922 NDA Ranbaxy Laboratories Inc. 10631-330 10631-330-05 500 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (10631-330-05)
XIMINO
minocycline hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL 201922 NDA Ranbaxy Laboratories Inc. 10631-330 10631-330-06 6 CAPSULE, EXTENDED RELEASE in 1 BLISTER PACK (10631-330-06)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrengthEQ 45MG BASE
Approval Date:Jul 11, 2012TE:RLD:No
Patent:► SubscribePatent Expiration:Feb 19, 2018Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
Patent:► SubscribePatent Expiration:Apr 2, 2027Product Flag?Substance Flag?Delist Request?
Patented Use:TREATMENT OF INFLAMMATORY LESIONS OF NON-NODULAR MODERATE TO SEVERE ACNE VULGARIS
Patent:► SubscribePatent Expiration:Apr 2, 2027Product Flag?YSubstance Flag?Delist Request?


Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Mallinckrodt
Express Scripts
Covington
Moodys
Teva
Fish and Richardson
Queensland Health
Boehringer Ingelheim
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot